Association of race with complications and prognosis following acute coronary syndromes

American Journal of Cardiology

Volumn 94, Issue 6, 2004, Pages 792-794

  Asher, Craig R ^a   Moliterno, David J ^b,g   Bhapkar, Manjushri V ^c   McGuire, Darren K ^d   Rao, Sunil V ^c   Holmes, David R ^e   Newby, L Kristin ^c   Bates, Eric R ^f   Topol, Eric J ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

^c DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^d UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^e MAYO CLINIC   (United States)

^f UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^g Division of Cardiovascular Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; SIBRAFIBAN;

ACUTE DISEASE; ADULT; AGED; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CARDIOVASCULAR SYMPTOM; CONTROLLED STUDY; DEMOGRAPHY; FEMALE; HEART MUSCLE ISCHEMIA; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; PROGNOSIS; RACE DIFFERENCE; RISK ASSESSMENT; RISK FACTOR; SURVIVAL RATE; SURVIVAL TIME; TREATMENT OUTCOME;

ACUTE DISEASE; AFRICAN AMERICANS; AGED; CORONARY DISEASE; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; OXIMES; PIPERIDINES; PLATELET AGGREGATION INHIBITORS; PROGNOSIS; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 4544220002     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2004.05.069     Document Type: Article

References (4)

1. The SYMPHONY Investigators Comparison of sibrafiban with aspirin for the prevention of cardiovascular events after acute coronary syndromes: a randomized trial Lancet 355 2000 337 345
2. Second SYMPHONY Investigators Randomized trial of aspirin, sibrafiban, or both for secondary prevention after acute coronary syndrome Circulation 103 2001 1727 1733
3. L.K. Newby for the SYMPHONY Steering Committee Long-term oral platelet glycoprotein IIb/IIIa receptor antagonism with sibrafiban after acute coronary syndromes: study design of the Sibrafiban Versus Aspirin to Yield Maximum Protection from Ischemic Heart Events Post-acute Coronary Syndromes (SYMPHONY) trial Am Heart J 138 1999 210 218
4. L.K. Newby, M.V. Bhapkar, H.D. White, E.J. Topol, F.C. Dougherty, R.A. Harrington, M.C. Smith, L.F. Asarch, R.M. Califf Predictors of 90-day outcome in patients stabilized after acute coronary syndromes Eur Heart J 24 2003 172 181